All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Bankruptcy Fears Burden Cancer Patients

April 9th 2015

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients.

Melanoma Excision Frequently Delayed in Medicare Population

April 8th 2015

One in five Medicare patients with melanoma waits more than 1.5 months after diagnosis to undergo surgery.

Three-Drug Combos, Immunotherapy Mark Future of Myeloma Management

April 8th 2015

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.

Colorectal Cancer Management Requires Multidisciplinary Approach

April 7th 2015

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

FDA Label Update Emphasizes Importance of RAS Testing in mCRC

April 7th 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

CTC Panel Shows Promise as Survival Surrogate in CRPC

April 7th 2015

A biomarker panel containing circulating tumor cell number and LDH level was shown to be a surrogate for overall survival in patients with metastatic castration-resistant prostate cancer.

Rucaparib Receives Breakthrough Designation for BRCA-Positive Advanced Ovarian Cancer

April 6th 2015

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Challenges, Need for New Therapies Remain in HCC

April 6th 2015

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

Future AACR President Discusses Her Leadership Goals and Research Experience

April 3rd 2015

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

STRIVE Data Further Demonstrate PFS Benefit With Enzalutamide Over Bicalutamide

April 2nd 2015

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Lung Cancer Pioneer Thomas Lynch Discusses the State of the Art

April 2nd 2015

Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.

FDA Approves New Oral Formulation of Deferasirox

March 31st 2015

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.

Study Suggests Lung Cancer Screening Criteria May Not Capture All Smokers Who Need It

March 31st 2015

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.

Hollings Cancer Center Researcher Receives Prestigious Governor's Award for Science

March 30th 2015

Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.

MCL Patients Progressing on Ibrutinib Respond Poorly to Salvage Therapy

March 30th 2015

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

Novel Agents, Combinations on Horizon for MCL

March 30th 2015

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

FDA Approves Abiraterone Pre-Chemo mCRPC Label Update

March 30th 2015

The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.

FDA Priority Review Granted to Carfilzomib sNDA in Myeloma

March 30th 2015

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

Costly New Drugs Could Lead to Generation of Have-Nots in CLL

March 26th 2015

Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.

SGR Repeal Bill Headed for Senate Following House Approval

March 26th 2015

A bill to repeal the SGR formula garnered critical support with a vote by the House of Representatives.